Study guide

3.3 Pathophysiological Bases of Diseases

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

3.3 Pathophysiological Bases of Diseases

Key Takeaways Explain This Topic AI

Ischemia and hypoxia collapse aerobic ATP generation, causing Na/K ATPase failure, cellular swelling, calcium influx, and either apoptosis (programmed, caspase-driven, non-inflammatory) or necrosis (pathologic, membrane rupture, inflammatory).

Acute inflammation is driven by neutrophils plus histamine, bradykinin, prostaglandins, and leukotrienes; chronic inflammation features macrophages, lymphocytes, granulomas, and fibrosis.

Thrombosis forms via Virchow's triad of endothelial injury, stasis, and hypercoagulability; embolism is a detached intravascular mass and infarction is ischemic necrosis of tissue downstream.

Benign tumors remain localized while malignant tumors invade and metastasize; the eight hallmarks of cancer include sustained proliferative signaling, evading growth suppressors, resisting apoptosis, replicative immortality, angiogenesis, invasion, metabolic reprogramming, and immune evasion.

Tumor suppressors such as p53, Rb, and APC restrain cell division, while oncogenes such as Ras, MYC, and HER2 drive proliferation when mutated or amplified.

Last updated: July 2026

Pathophysiology describes the functional changes that accompany disease. The FPGEE expects you to link cellular injury, inflammation, hemodynamic disorders, and neoplasia to the clinical presentations you will encounter in pharmacy practice.

Cellular Injury

Cells are injured when oxygen, nutrients, or waste removal fail. Ischemia blocks blood flow; hypoxia reduces oxygen delivery. Both collapse aerobic ATP generation, causing Na/K ATPase failure, cellular swelling, and calcium influx. Reperfusion injury worsens damage when oxidative phosphorylation restarts and generates reactive oxygen species (ROS) . Oxidative stress overwhelms endogenous antioxidants such as glutathione, superoxide dismutase, and catalase. Persistent injury triggers apoptosis (programmed, energy-requiring, caspase-driven, no inflammation) or necrosis (pathologic, ATP-depleted, membrane rupture, inflammation). Liquefactive necrosis occurs in brain infarcts and abscesses; coagulative necrosis in myocardial and kidney infarcts; caseous necrosis in tuberculosis; fat necrosis in acute pancreatitis.

Inflammation

Acute inflammation is the early vascular and cellular response to injury. Vascular changes (vasodilation, increased permeability) deliver plasma proteins; neutrophils emigrate via margination, rolling, adhesion, and diapedesis. Mediators include histamine (vasodilation, bronchoconstriction), bradykinin (pain, vasodilation), prostaglandins (fever, pain, vasodilation via COX), leukotrienes (bronchoconstriction, vascular permeability via 5-lipoxygenase), and cytokines (IL-1, IL-6, and TNF-alpha for systemic effects such as fever and acute-phase reactants).

Chronic inflammation features macrophages, lymphocytes, and plasma cells. Granulomatous inflammation (tuberculosis, sarcoidosis, Crohn disease) organizes activated macrophages into epithelioid cells with multinucleated giant cells. Fibroblast activation leads to fibrosis , the scar tissue that replaces parenchyma when regeneration fails.

  • Feature Acute Inflammation Chronic Inflammation
  • Duration Minutes to days Weeks to years
  • Predominant cells Neutrophils Macrophages, lymphocytes, plasma cells
  • Key mediators Histamine, bradykinin, prostaglandins, leukotrienes Cytokines, growth factors, IFN-gamma
  • Typical outcome Resolution or progression Fibrosis and scarring
  • Prototype Appendicitis, bacterial pneumonia Tuberculosis, rheumatoid arthritis
  • Tissue Repair

Repair proceeds through hemostasis, inflammation, proliferation (fibroblast and angiogenic), and remodeling. Labile cells (epithelium, bone marrow) regenerate continuously. Stable cells (liver, kidney) regenerate when injured but are otherwise quiescent. Permanent cells (neurons, cardiac myocytes) cannot divide, so injury heals by scarring rather than regeneration. Wound healing phases are tightly regulated: platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta) drive fibroblast migration and collagen synthesis, while vascular endothelial growth factor (VEGF) initiates angiogenesis. Vitamin C is required for collagen cross-linking (scurvy causes impaired wound healing), and zinc deficiency delays epithelialization. Chronic wounds (diabetic foot ulcers, pressure injuries) stall in the inflammatory phase because of repeated ischemia, infection, or biofilm.

Hemodynamic Disorders

Edema is excess interstitial fluid from increased hydrostatic pressure, decreased oncotic pressure, lymphatic obstruction, or sodium retention. Hyperemia is active arteriolar dilation (inflammation, exercise); congestion is impaired venous outflow (right heart failure, cirrhosis). Hemorrhage is blood escaping the vasculature. Thrombosis forms clots in intact vessels via Virchow's triad : endothelial injury, abnormal blood flow (stasis or turbulence), and hypercoagulability. Embolism is a detached intravascular mass — pulmonary embolism, fat embolism, air embolism, or septic embolism. Infarction is ischemic necrosis of tissue; red infarcts occur with venous occlusion or loose tissue (lung, intestine), while white infarcts occur in solid organs with end-arterial supply (heart, kidney, spleen).

Neoplasia

Neoplasms are autonomous new growths. Benign tumors remain localized, grow expansively, and rarely recur. Malignant tumors invade surrounding tissue, metastasize, and recur. The hallmarks of cancer (Hanahan and Weinberg) include sustained proliferative signaling, evading growth suppressors, resisting apoptosis, enabling replicative immortality (telomerase), inducing angiogenesis, activating invasion and metastasis, reprogramming energy metabolism (Warburg effect), and evading immune destruction.

Tumor suppressors (p53, Rb, APC) restrain cell division; their loss removes the brakes. Oncogenes (Ras, MYC, HER2) drive proliferation when mutated or amplified. Metastasis occurs via lymphatic spread (typical of carcinomas), hematogenous spread (sarcomas, renal cell, hepatocellular), seeding of body cavities (ovarian), and direct extension. Common metastatic sites include liver, lung, bone, and brain.

Chemotherapy and targeted therapy exploit these mechanisms: antimetabolites (methotrexate, 5-FU) disrupt DNA synthesis in rapidly dividing cells; alkylating agents (cyclophosphamide) cross-link DNA; platinum compounds (cisplatin) form adducts; anthracyclines (doxorubicin) intercalate DNA and generate ROS but are cardiotoxic; taxanes (paclitaxel) stabilize microtubules; vinca alkaloids (vincristine) inhibit microtubule polymerization causing peripheral neuropathy; tyrosine kinase inhibitors (imatinib for BCR-ABL, erlotinib for EGFR, sorafenib and sunitinib for VEGFR/PDGFR) block oncogenic signaling; monoclonal antibodies (trastuzumab for HER2, rituximab for CD20, cetuximab for EGFR) bind surface antigens; immune checkpoint inhibitors (nivolumab, pembrolizumab block PD-1; ipilimumab blocks CTLA-4) release T-cell responses but cause immune-related adverse events (colitis, pneumonitis, hepatitis, endocrinopathies).

Genetic and Systemic Pathophysiology

Genetic disease ranges from single-nucleotide mutations (sickle cell disease, cystic fibrosis) to chromosomal aneuploidies (trisomy 21, Turner syndrome) to polygenic disorders. Shock is systemic circulatory failure with several forms: hypovolemic (hemorrhage, burns, dehydration), cardiogenic (myocardial infarction, heart failure), septic (infection-driven vasodilation and capillary leak), and anaphylactic (Type I hypersensitivity causing massive vasodilation). The systemic inflammatory response underlies sepsis, severe trauma, and pancreatitis through a cytokine cascade (TNF-alpha, IL-1, IL-6) that can progress to multi-organ dysfunction syndrome.

Amyloidosis results from misfolded proteins depositing as beta-pleated sheets in tissues; AL amyloidosis arises from monoclonal light chains (plasma cell dyscrasia), AA amyloidosis from chronic inflammation (serum amyloid A), and hereditary forms from transthyretin mutations. Presentation includes nephrotic syndrome, restrictive cardiomyopathy, and macroglossia; diagnosis is Congo-red-positive biopsy. Atherosclerosis begins with endothelial injury, LDL infiltration, foam cell formation, fatty streaks, fibrous plaque, and ultimately ruptured plaque with thrombosis — the substrate of most myocardial infarctions and ischemic strokes. Risk factor modification (statins, antihypertensives, smoking cessation, glycemic control) targets the modifiable drivers of plaque progression.

Hallmarks of Cancer